Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-05-15
DOI
10.1016/s1470-2045(21)00126-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- (2021) Ahmet Sezer et al. LANCET
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
- (2020) Michael R Migden et al. LANCET ONCOLOGY
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies
- (2020) Dulce M. Barrios et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
- (2020) Danny Rischin et al. Journal for ImmunoTherapy of Cancer
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase 2 randomised, double‐blind BOLT study
- (2019) R. Dummer et al. BRITISH JOURNAL OF DERMATOLOGY
- Emerging trends in the treatment of advanced basal cell carcinoma
- (2018) Michael R. Migden et al. CANCER TREATMENT REVIEWS
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study
- (2018) Anne Lynn S. Chang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Update on Keratinocyte Carcinomas
- (2018) Kishwer S. Nehal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
- (2017) N. Basset-Séguin et al. EUROPEAN JOURNAL OF CANCER
- Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
- (2017) Brigitte Dréno et al. LANCET ONCOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
- (2016) Gerald S. Falchook et al. Journal for ImmunoTherapy of Cancer
- Management of high-risk and advanced basal cell carcinoma
- (2015) S. Puig et al. Clinical & Translational Oncology
- Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
- (2015) Aleksandar Sekulic et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
- (2015) Michael R Migden et al. LANCET ONCOLOGY
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
- (2014) L. E. Macdonald et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
- (2014) A. J. Murphy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Basal-Cell Carcinoma Incidence and Associated Risk Factors in US Women and Men
- (2013) S. Wu et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Hedgehog Signaling Controls T Cell Killing at the Immunological Synapse
- (2013) M. de la Roche et al. SCIENCE
- Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
- (2012) Anne Lynn S. Chang et al. ARCHIVES OF DERMATOLOGY
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas
- (2010) A. Walter et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More